Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Obesity Treatments

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

Full results are slated for presentation at the American Diabetes Association meeting in June.

Eli Lilly’s Tirzepatide Surge Collides With Rich-Valuation Concerns

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

Novo Nordisk Sues Hims & Hers to Halt Compounded Wegovy Copycats

Novo Nordisk Forecasts Up to 13% 2026 Sales and Profit Decline as U.S. Price Cuts Bite

Pfizer’s Monthly Obesity Shot Shows Mid-Stage Gains With Up to 12.3% Weight Loss

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Novo Nordisk Raises Metsera Bid to $10 Billion, Outpacing Pfizer’s $8.1 Billion Counter

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study

Lilly’s Orforglipron Pill Hits Phase 3 Goals, Clearing Path to Global Filings

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial